Researcher Publications

Lauren M. Aleksunes, PharmD, PhD, DABT

Selected Publications

George B, Wen X, Mercke N, Gomez M, O’Bryant C, Bowles D, Hu Y, Hogan S, Joy M, Aleksunes L (2020) Time-dependent changes in kidney injury biomarkers in patients receiving multiple cycles of cisplatin. Toxicol Rep. 7:571-576. PMCID:PMC32382514.
Ibrahim M, Chang C, Hu Y, Hogan S, Mercke N, Gomez M, O’Bryant C, Bowles D, George B, Wen X, Buckley B, Aleksunes L, Joy M (2019) Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. Euro J Clin Pharmacol. 75(1):51-57.
Russo D, Strickland J, Karmaus A, Wang W, Shende S, Hartung T, Aleksunes L, Zhu H (2019) Non-animal models for acute toxicity evaluations: applying data-driven profiling and mechanism-driven read-across. Environ Health Persp. 127(4):47001. 127:47001. PMCID:PMC6785238
Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. George B, Joy MS, Aleksunes LM. Exp Biol Med (Maywood). 2018 Feb;243(3):272-282. doi: 10.1177/1535370217745302. Epub 2017 Dec 12. PMID:29231123
Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant C, Bowles DW, George B, Wen X, Aleksunes LM, Joy MS. Int J Mol Sci. 2017 Jun 22;18(7)
Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity. George B, Wen X, Mercke N, Gomez M, O'Bryant C, Bowles DW, Hu Y, Hogan SL, Joy MS, Aleksunes LM. Clin Pharmacol Ther. 2017 Apr;101(4):510-518
Xenobiotic transporters and kidney injury. George B, You D, Joy MS, Aleksunes LM. Adv Drug Deliv Rev. 2017 Jul 1;116:73-91
In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants. Wen X, Joy MS, Aleksunes LM. Pharm Res. 2017 Aug;34(8):1637-1647.
Bardoxolone methyl modulates efflux transporter and detoxifying enzyme expression in cisplatin-induced kidney cell injury. Atilano-Roque A, Aleksunes LM, Joy MS. Toxicol Lett. 2016 Sep 30;259:52-9.
Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice. Wen X, Buckley B, McCandlish E, Goedken MJ, Syed S, Pelis R, Manautou JE, Aleksunes LM. Am J Pathol. 2014 May;184(5):1299-308.
Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, Klaassen CD. J Pharmacol Exp Ther. 2010 Oct;335(1):2-12.
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Klaassen CD, Aleksunes LM. Pharmacol Rev. 2010 Mar;62(1):1-96.
Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Aleksunes LM, Augustine LM, Scheffer GL, Cherrington NJ, Manautou JE. Toxicology. 2008 Sep 4;250(2-3):82-8.

Return to member profile